Simone Marnitz1, Peter Martus2, Christhardt Köhler3, Carmen Stromberger4, Elke Asse5, Peter Mallmann6, Heinz Schmidberger7, Renato José Affonso Júnior8, João Soares Nunes9, Jalid Sehouli10, Volker Budach4. 1. Department of Radiation Oncology, University of Cologne Medical Faculty, Cologne, Germany. Electronic address: simone.marnitz-schulze@uk-koeln.de. 2. Institute for Clinical Epidemiology and Applied Biostatistics, Eberhard-Karls-Universität Tübingen, Tübingen, Germany. 3. Department of Advanced Operative and Oncologic Gynecology, Asklepios Clinics, Hamburg, Germany. 4. Department of Radiation Oncology, University of Cologne Medical Faculty, Cologne, Germany. 5. Department of Radiation Oncology, University Hospital Greifswald, Greifswald, Germany. 6. Department of Gynecology and Obstetrics, University Hospital Cologne, Cologne, Germany. 7. Department of Radiation Oncology, University of Mainz, Mainz, Germany. 8. Department of Radiation Oncology, Hospital de Cãncer de Barretos, Barretos, Brazil. 9. Department of Clinical Oncology, Hospital de Cãncer de Barretos, Barretos, Brazil. 10. Department of Gynecology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Abstract
PURPOSE: The Uterus-11 trial was designed to evaluate the role of surgical staging in patients with cervical cancer before primary chemoradiation therapy (CRT). The present report provides the toxicity data stratified by the treatment arm and technique. METHODS AND MATERIALS: A total of 255 patients with carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics stage IIB-IVA) were randomized to either surgical staging followed by CRT (arm A) or clinical staging followed by CRT (arm B). Patients with para-aortic metastases underwent extended field radiation therapy (RT). Brachytherapy was mandatory. The present report presents the acute therapy-related toxicities stratified by treatment arm and radiation technique. RESULTS: A total of 240 patients were eligible (n=121 in arm A; n=119 in arm B). Of the 240 patients, 236 (98.3%) underwent external beam RT with a median total dose of 50.4 Gy. The mean treatment duration was 53 days. Of the patients, 60% underwent intensity modulated RT (IMRT). A total of 234 patients (97.5%) underwent chemotherapy, and 231 (96.3%) underwent brachytherapy, with a median single dose of 6 Gy covering the tumor to a median nominal total dose of 28 Gy. Treatment was well tolerated, with 0% grade ≥3 genitourinary and gastrointestinal toxicity, 6% grade 3 nausea, 3% grade 3 vomiting, and <2% grade 3 diarrhea. More patients after surgical staging experienced grade 2 anemia (54.3% in arm A vs 45.3% in arm B; P=.074) and grade 2 leukocytopenia (41.4% vs 31.6%; P=.56). Of the patients who received IMRT versus a 3-dimensional technique, 65.3% versus 33.7% presented with grade 2 anemia. Grade 3 gastrointestinal and grade 2 bladder toxicity were significantly reduced with the use of IMRT. CONCLUSIONS: The incidence and severity of acute therapy-related toxicity compared favorably with those from other randomized trials. Excellent adherence to treatment and treatment quality was achieved compared with patterns of care analyses. Surgical staging led to a doubled number of patients treated with extended field RT. The question of whether surgical staging is beneficial in the context of primary CRT requires further study.
RCT Entities:
PURPOSE: The Uterus-11 trial was designed to evaluate the role of surgical staging in patients with cervical cancer before primary chemoradiation therapy (CRT). The present report provides the toxicity data stratified by the treatment arm and technique. METHODS AND MATERIALS: A total of 255 patients with carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics stage IIB-IVA) were randomized to either surgical staging followed by CRT (arm A) or clinical staging followed by CRT (arm B). Patients with para-aortic metastases underwent extended field radiation therapy (RT). Brachytherapy was mandatory. The present report presents the acute therapy-related toxicities stratified by treatment arm and radiation technique. RESULTS: A total of 240 patients were eligible (n=121 in arm A; n=119 in arm B). Of the 240 patients, 236 (98.3%) underwent external beam RT with a median total dose of 50.4 Gy. The mean treatment duration was 53 days. Of the patients, 60% underwent intensity modulated RT (IMRT). A total of 234 patients (97.5%) underwent chemotherapy, and 231 (96.3%) underwent brachytherapy, with a median single dose of 6 Gy covering the tumor to a median nominal total dose of 28 Gy. Treatment was well tolerated, with 0% grade ≥3 genitourinary and gastrointestinal toxicity, 6% grade 3 nausea, 3% grade 3 vomiting, and <2% grade 3 diarrhea. More patients after surgical staging experienced grade 2 anemia (54.3% in arm A vs 45.3% in arm B; P=.074) and grade 2 leukocytopenia (41.4% vs 31.6%; P=.56). Of the patients who received IMRT versus a 3-dimensional technique, 65.3% versus 33.7% presented with grade 2 anemia. Grade 3 gastrointestinal and grade 2 bladder toxicity were significantly reduced with the use of IMRT. CONCLUSIONS: The incidence and severity of acute therapy-related toxicity compared favorably with those from other randomized trials. Excellent adherence to treatment and treatment quality was achieved compared with patterns of care analyses. Surgical staging led to a doubled number of patients treated with extended field RT. The question of whether surgical staging is beneficial in the context of primary CRT requires further study.
Authors: Lucas Gomes Sapienza; Maria José Leite Gomes; Vinicius Fernando Calsavara; Mario M Leitao; Glauco Baiocchi Journal: Gynecol Oncol Date: 2016-11-28 Impact factor: 5.482
Authors: Junzo Chino; Christina M Annunziata; Sushil Beriwal; Lisa Bradfield; Beth A Erickson; Emma C Fields; KathrynJane Fitch; Matthew M Harkenrider; Christine H Holschneider; Mitchell Kamrava; Eric Leung; Lilie L Lin; Jyoti S Mayadev; Marc Morcos; Chika Nwachukwu; Daniel Petereit; Akila N Viswanathan Journal: Pract Radiat Oncol Date: 2020-05-18
Authors: Salim Abraham Barquet-Muñoz; Gabriel Jaime Rendón-Pereira; Denise Acuña-González; Monica Vanessa Heymann Peñate; Luis Alonso Herrera-Montalvo; Lenny Nadia Gallardo-Alvarado; David Francisco Cantú-de León; René Pareja Journal: World J Surg Oncol Date: 2017-01-14 Impact factor: 2.754
Authors: Hima Bindu Musunuru; Phillip M Pifer; Pranshu Mohindra; Kevin Albuquerque; Sushil Beriwal Journal: Indian J Med Res Date: 2021-08 Impact factor: 5.274